Kiavasch M N Farid, Stefan Schönland, Norbert Blank, Fabian Aus dem Siepen, Markus Weiler, Jörg Beimler, Ute Hegenbart
{"title":"[Amyloidosis: classification, diagnosis, and treatment].","authors":"Kiavasch M N Farid, Stefan Schönland, Norbert Blank, Fabian Aus dem Siepen, Markus Weiler, Jörg Beimler, Ute Hegenbart","doi":"10.1007/s00108-026-02130-4","DOIUrl":null,"url":null,"abstract":"<p><p>Amyloidoses are rare protein-misfolding disorders characterized by the deposition of insoluble fibrillar aggregates, leading to potentially life-threatening organ damage. These deposits can be systemic or localized. Systemic amyloidoses are often associated with monoclonal gammopathies, chronic inflammatory conditions, or have a hereditary origin. Treatment strategies primarily focus on reducing the production of amyloidogenic proteins-depending on the specific protein and its origin-through therapies such as chemotherapy, anti-inflammatory agents, or gene-silencing approaches. Early diagnosis is crucial to prevent progressive organ dysfunction. Over the past 25 years, significant advances in the diagnosis and therapeutic management of amyloidosis have been made.</p>","PeriodicalId":73385,"journal":{"name":"Innere Medizin (Heidelberg, Germany)","volume":" ","pages":"882-891"},"PeriodicalIF":0.6000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innere Medizin (Heidelberg, Germany)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00108-026-02130-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Amyloidoses are rare protein-misfolding disorders characterized by the deposition of insoluble fibrillar aggregates, leading to potentially life-threatening organ damage. These deposits can be systemic or localized. Systemic amyloidoses are often associated with monoclonal gammopathies, chronic inflammatory conditions, or have a hereditary origin. Treatment strategies primarily focus on reducing the production of amyloidogenic proteins-depending on the specific protein and its origin-through therapies such as chemotherapy, anti-inflammatory agents, or gene-silencing approaches. Early diagnosis is crucial to prevent progressive organ dysfunction. Over the past 25 years, significant advances in the diagnosis and therapeutic management of amyloidosis have been made.